<?xml version='1.0' encoding='utf-8'?>
<document id="26542068"><sentence text="Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection."><entity charOffset="0-11" id="DDI-PubMed.26542068.s1.e0" text="Daclatasvir" /></sentence><sentence text="The treatment of chronic hepatitis C is revolutionizing rapidly" /><sentence text=" The aim of this study is to review the efficacy and safety of daclatasvir (DCV)-containing all-oral regimens in clinical studies for chronic hepatitis C treatment"><entity charOffset="63-74" id="DDI-PubMed.26542068.s3.e0" text="daclatasvir" /><entity charOffset="76-79" id="DDI-PubMed.26542068.s3.e1" text="DCV" /><pair ddi="false" e1="DDI-PubMed.26542068.s3.e0" e2="DDI-PubMed.26542068.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26542068.s3.e0" e2="DDI-PubMed.26542068.s3.e1" /></sentence><sentence text=" Using PubMed and search terms of 'DCV,' 'hepatitis C virus (HCV) treatment,' and 'HCV NS5A inhibitors,' literature on the clinical development of DCV, as well as abstracts presented at the April 2015 annual meeting of the European Association for the Study of the Liver (EASL) and November 2014 annual meeting of the American Association for the Study of Liver Diseases were reviewed"><entity charOffset="35-37" id="DDI-PubMed.26542068.s4.e0" text="DCV" /><entity charOffset="147-149" id="DDI-PubMed.26542068.s4.e1" text="DCV" /><pair ddi="false" e1="DDI-PubMed.26542068.s4.e0" e2="DDI-PubMed.26542068.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26542068.s4.e0" e2="DDI-PubMed.26542068.s4.e1" /></sentence><sentence text=" The final search was undertaken on 14 July 2015" /><sentence text=" With its potent antiviral activity to all HCV genotypes (GT) demonstrated in preclinical, phases 1-3 studies, DCV has been acting as a very competent team player in clinical trials of all-oral regimens"><entity charOffset="111-113" id="DDI-PubMed.26542068.s6.e0" text="DCV" /></sentence><sentence text=" It is generally safe and well tolerated with a low genetic barrier to resistance and low potential for drug-drug interaction" /><sentence text=" Administered with a non-structural protein 3 (NS3) protease inhibitor (asunaprevir, ASV) with or without a non-nucleoside NS5B polymerase inhibitor (beclabuvir, BCV), or a nucleotide NS5B polymerase inhibitor (sofosbuvir, SOF), DCV is able to achieve greater than a 90-% HCV eradication rate in both treatment-naïve and treatment-experienced patients with GT 1"><entity charOffset="211-221" id="DDI-PubMed.26542068.s8.e0" text="sofosbuvir" /><entity charOffset="229-238" id="DDI-PubMed.26542068.s8.e1" text="DCV" /><pair ddi="false" e1="DDI-PubMed.26542068.s8.e0" e2="DDI-PubMed.26542068.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26542068.s8.e0" e2="DDI-PubMed.26542068.s8.e1" /></sentence><sentence text=" A triple combination regimen with DCV/ASV/BCV results in 100% sustained virologic response (SVR) rates in HCV GT 4 treatment-naïve subjects"><entity charOffset="35-37" id="DDI-PubMed.26542068.s9.e0" text="DCV" /></sentence><sentence text=" DCV/SOF combination also had demonstrated up to 90-% SVR rates in GT 3-infected non-cirrhotic patients"><entity charOffset="1-3" id="DDI-PubMed.26542068.s10.e0" text="DCV" /></sentence><sentence text=" The efficacy and safety of DCV-containing all-oral regimens highlight a new era of interferon-free therapy for chronic hepatitis C"><entity charOffset="28-30" id="DDI-PubMed.26542068.s11.e0" text="DCV" /></sentence><sentence text="" /></document>